Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Overweight or Obesity
Clinical trial register · United States · industry-sponsored

Overweight or Obesity Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9159 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Oct 2026, 03:16 UTC
9159
Studies in scope
industry-sponsored, all four open statuses
4969
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 9 Florida 9 Illinois 6 Arizona 6 Georgia 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company5 Regeneron Pharmaceuticals3 Clinical Nutrition Research Center, Illinois Institute of Technology2 Pfizer2 BrightGene Bio-Medical Technology Co., Ltd.1
State
California9 Florida9 Illinois6 Arizona6 Georgia6
All 20 states
Target enrolment
to

Overweight or Obesity trials in the USA

13 of 9159 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Regeneron Pharmaceuticals
Phase 2
360
Alabama, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Nebraska
2026-07-28
Recruiting
Regeneron Pharmaceuticals
Phase 1
90
California
2026-06-29
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Active, closed
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Texas
2026-03-16
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
BrightGene Bio-Medical Technology Co., Ltd.
Phase 1
60
Maryland
2025-10-09
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Pfizer
Phase 2
268
Florida, Georgia, New Jersey
2025-04-07
Recruiting
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Active, closed
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Active, closed
Eli Lilly and Company
Phase 3
3,127
Arizona, California, Colorado, Florida, Georgia, Hawaii, Idaho, Kansas
2023-06-05
Active, closed
Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human
NCT04267705Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
Clinical Nutrition Research Center, Illinois Institute of Technology
Not applicable
103
Illinois
2020-02-24
Active, closed
Berries, Inflammation, and Gut Microbiome
NCT04100200Overweight or Obesity, Healthy
Clinical Nutrition Research Center, Illinois Institute of Technology
Not applicable
105
Illinois
2019-10-07
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/overweight-or-obesity

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,159 studies in total at the last sync on 24 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Overweight or Obesity.

How many Overweight or Obesity trials are recruiting in the US?

4 of the 13 studies on this page are recruiting new participants as of the 24 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Overweight or Obesity), 13 studies
PhaseStudiesRecruitingShare
Phase 24130.8%
Phase 33123.1%
Not applicable2015.4%
Phase 12115.4%
Phase 42115.4%

Most active sponsors

Lead sponsors with the most studies (Overweight or Obesity)
Lead sponsorStudiesRecruiting
Eli Lilly and Company52
Regeneron Pharmaceuticals32
Clinical Nutrition Research Center, Illinois Institute of Technology20
Pfizer20
BrightGene Bio-Medical Technology Co., Ltd.10

Top states

Top states (Overweight or Obesity), by number of studies with a site there
StateStudies
California9
Florida9
Arizona6
Georgia6
Illinois6
Maryland5
Kansas3
Alabama2
Colorado2
Connecticut2
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.